{"id":171190,"date":"2026-06-15T13:16:28","date_gmt":"2026-06-15T13:16:28","guid":{"rendered":"https:\/\/www.m3globalresearch.com\/blog\/?p=171190"},"modified":"2026-06-15T13:55:22","modified_gmt":"2026-06-15T13:55:22","slug":"study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma","status":"publish","type":"post","link":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/","title":{"rendered":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"171190\" class=\"elementor elementor-171190\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7b2c08d e-con e-atomic-element e-flexbox-base e-d693f31 \" data-id=\"7b2c08d\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"7b2c08d\" data-e-type=\"e-flexbox\" data-id=\"7b2c08d\">\n    \t\t<div class=\"elementor-element elementor-element-fac4392 elementor-widget elementor-widget-text-editor\" data-id=\"fac4392\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Researchers at Yale University, Massachusetts General Hospital, the Weizmann Institute of Science, and the University of Miami have identified two distinct patterns of tumour evolution in IDH-mutant glioma. This incurable brain cancer most commonly affects adults in their 30s and 40s. The findings, published in Nature, shed light on how these tumours shift from treatment-sensitive states at initial diagnosis to treatment-resistant states at recurrence.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b12c334 elementor-widget elementor-widget-text-editor\" data-id=\"b12c334\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>The study analysed molecular data from tumours collected across multiple time points from 35 patients with IDH-mutant glioma. Rather than relying solely on bulk tumour sequencing, the team integrated DNA sequencing, single-cell RNA sequencing, and single-cell chromatin accessibility profiling. This combination allowed the researchers to track genetic changes over time, measure gene activity in individual tumour cells, and identify which regions of the genome were active, linking specific genetic events to the cellular states that emerge as tumours recur.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f241f77 elementor-widget elementor-widget-text-editor\" data-id=\"f241f77\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>The analysis revealed a clear divergence in recurrence patterns. In some patients, tumours remained relatively stable, with limited genetic and cellular change. In others, recurrent tumours acquired new genetic alterations and transitioned towards more aggressive cellular programmes, including stem cell-like and highly proliferative cell states, alongside changes in the tumour microenvironment characterised by immune-suppressive cell populations. This latter pattern bore close resemblance to features observed in glioblastoma, the most lethal form of brain cancer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bcdb794 elementor-widget elementor-widget-text-editor\" data-id=\"bcdb794\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>The group showing substantial genetic change at recurrence demonstrated reduced sensitivity to treatment, potentially explaining why certain tumours become increasingly difficult to manage following initial therapy. The authors emphasise that current treatments remain beneficial and that this work aims to identify earlier when and why tumours lose treatment sensitivity, to inform more effective subsequent therapeutic strategies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bb5aaf1 elementor-widget elementor-widget-text-editor\" data-id=\"bb5aaf1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Source: <em>Johnson KC et al. Acquired genetic and cell-state changes in IDH-mutant glioma progression. Nature (2026). DOI: 10.1038\/s41586-026-10612-6.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.<\/p>\n","protected":false},"author":11,"featured_media":171245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3200],"tags":[2875],"class_list":["post-171190","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-medical-news","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma<\/title>\n<meta name=\"description\" content=\"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma\" \/>\n<meta property=\"og:description\" content=\"Stage 2 chronic kidney disease often goes unnoticed, with estimated glomerular filtration rate levels still within the kidney function threshold.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/\" \/>\n<meta property=\"og:site_name\" content=\"M3 Global Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:16:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:55:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Admin B.\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:site\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin B.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/\"},\"author\":{\"name\":\"Admin B.\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\"},\"headline\":\"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma\",\"datePublished\":\"2026-06-15T13:16:28+00:00\",\"dateModified\":\"2026-06-15T13:55:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Brain-cancer-1-scaled.jpeg\",\"keywords\":[\"oncology\"],\"articleSection\":[\"Latest Medical News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/\",\"name\":\"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Brain-cancer-1-scaled.jpeg\",\"datePublished\":\"2026-06-15T13:16:28+00:00\",\"dateModified\":\"2026-06-15T13:55:22+00:00\",\"description\":\"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Brain-cancer-1-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Brain-cancer-1-scaled.jpeg\",\"width\":2560,\"height\":1709,\"caption\":\"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"name\":\"M3 Global Research\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\",\"name\":\"M3 Global Research\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":null,\"contentUrl\":null,\"width\":null,\"height\":null,\"caption\":\"M3 Global Research\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/en-gb.facebook.com\\\/M3GlobalResearch\\\/\",\"https:\\\/\\\/x.com\\\/M3GR_Community\",\"https:\\\/\\\/www.instagram.com\\\/m3globalresearch\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/10557915\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\",\"name\":\"Admin B.\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"caption\":\"Admin B.\"},\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/author\\\/admin-b\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma","description":"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/","og_locale":"en_US","og_type":"article","og_title":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma","og_description":"Stage 2 chronic kidney disease often goes unnoticed, with estimated glomerular filtration rate levels still within the kidney function threshold.","og_url":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/","og_site_name":"M3 Global Research","article_publisher":"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","article_published_time":"2026-06-15T13:16:28+00:00","article_modified_time":"2026-06-15T13:55:22+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","type":"image\/jpeg"}],"author":"Admin B.","twitter_card":"summary_large_image","twitter_creator":"@M3GR_Community","twitter_site":"@M3GR_Community","twitter_misc":{"Written by":"Admin B.","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#article","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/"},"author":{"name":"Admin B.","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b"},"headline":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma","datePublished":"2026-06-15T13:16:28+00:00","dateModified":"2026-06-15T13:55:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","keywords":["oncology"],"articleSection":["Latest Medical News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/","url":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/","name":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#primaryimage"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","datePublished":"2026-06-15T13:16:28+00:00","dateModified":"2026-06-15T13:55:22+00:00","description":"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence.","breadcrumb":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#primaryimage","url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","contentUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","width":2560,"height":1709,"caption":"New research reveals how idh-mutant glioma evolves into treatment-resistant disease, offering insights into brain cancer and glioma recurrence."},{"@type":"BreadcrumbList","@id":"https:\/\/www.m3globalresearch.com\/blog\/study-maps-two-distinct-pathways-of-treatment-resistance-in-recurring-idh-mutant-glioma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.m3globalresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Study Maps Two Distinct Pathways of Treatment Resistance in Recurring IDH-Mutant Glioma"}]},{"@type":"WebSite","@id":"https:\/\/www.m3globalresearch.com\/blog\/#website","url":"https:\/\/www.m3globalresearch.com\/blog\/","name":"M3 Global Research","description":"","publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m3globalresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization","name":"M3 Global Research","url":"https:\/\/www.m3globalresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/","url":null,"contentUrl":null,"width":null,"height":null,"caption":"M3 Global Research"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","https:\/\/x.com\/M3GR_Community","https:\/\/www.instagram.com\/m3globalresearch","https:\/\/www.linkedin.com\/company\/10557915"]},{"@type":"Person","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b","name":"Admin B.","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","caption":"Admin B."},"url":"https:\/\/www.m3globalresearch.com\/blog\/author\/admin-b\/"}]}},"jetpack_featured_media_url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/Brain-cancer-1-scaled.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=171190"}],"version-history":[{"count":17,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171190\/revisions"}],"predecessor-version":[{"id":171267,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171190\/revisions\/171267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media\/171245"}],"wp:attachment":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=171190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=171190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=171190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}